Myriad(US:MYGN) Globenewswireยท2025-10-14 12:00Core Insights - Myriad Genetics has added two genes, F8 and FXN, to its Foresight Carrier Screen Universal Plus Panel, enhancing its compliance with the American College of Medical Genetics and Genomics recommendations [1][4]. Gene-Specific Information - Variants in the F8 gene are associated with hemophilia A, a hereditary bleeding disorder that can lead to prolonged bleeding [2]. - The FXN gene is linked to Friedreich's ataxia, a rare neurodegenerative disease that causes motor weakness and sensory loss [3]. Product Features and Impact - The Foresight Carrier Screen is designed to provide vital genetic insights for informed family planning, with a detection rate of one in 22 couples for serious inherited conditions [6]. - The Foresight Carrier Screen has been validated through over 20 peer-reviewed publications and is the only expanded carrier screening test with published analytical validation in the US [5]. Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on improving patient care and reducing healthcare costs through molecular insights [7].